Musculoskeletal Abnormalities

7

Review clinical trials related to Musculoskeletal Abnormalities. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Comparing Two Soft Tissues Technique on Piriformis Syndrome Patients

Piriformis Syndrome is a neuromuscular condition with symptoms of pain, numbness and tingling tracing the route of the sciatic nerve, due to the nerve impingement by the piriformis muscle. Two common manual therapy techniques used to treat musculoskeletal conditions are myofascial release and post-isometric relaxation. The intent of the research is to evaluate the effects of myofascial release (MFR) as compared to post-isometric relaxation (PIR) in improving pain and lower extremity function in piriformis syndrome (LEFS). The study population involved 32 individuals aged between 20 to 50 years who will be randomly assigned to two groups; a group that received MFR and a group that received PIR. Both groups received the baseline treatment for four weeks. The Visual Analog Scale (VAS) will be employed to gauge the amount of pain, while the LEFS was used to measure functional mobility

Participants needed: 26
Trial details
Age: 20-50Biological sex: AllType: InterventionalSponsor: University of FaisalabadUpdated: Jun 30, 2026Locations: 1
Eligibility criteria

Positive Lasegue sign [+3]

Lower extremity injuries including ligament, tendon injuries, muscle strains as... [+8]

Status: Recruiting

GLP-1R Actions on Muscle and the Skeleton

The GRAMS study objectives are to assess the musculoskeletal changes that occur after weight loss using GLP-1 based therapy. A lifestyle intervention with diet and exercise is included to assess any mitigating effects are provided, versus a control group with regular exercise and diet.

Participants needed: 50
Trial details
Phase: Phase 4Age: 18-50Biological sex: AllType: InterventionalSponsor: Pennington Biomedical Research CenterUpdated: May 29, 2026Locations: 1
Eligibility criteria

Subjects will have a BMI between 30kg/m2 [+8]

Menopausal females. [+17]

Status: Recruiting

Advanced Surgical Simulation Processes in the Correction of Skeletal Defects and Deformities

Virtual Surgical Planning (VSP), Computer-Aided Surgical Simulation (CASS) for bone corrections, and the customization of implants and devices through 3D printing, known as Patient-Specific Instruments (PSI) and Graft-Specific Instruments (GSI), are assuming increasingly central roles in orthopedic clinical and surgical practice. One area witnessing notable advancement is the treatment of musculoskeletal disorders (MMS) in children, adolescents, and young adults. These disorders involve severe and rare abnormalities in skeletal formation and development across three-dimensional planes, often affecting multiple limbs. Managing such deformities is complex, challenging to standardize, and prone to unpredictable clinical, radiographic, and functional outcomes. The application of 3D modeling and printing technologies offers a deeper understanding of deformities and facilitates improved prediction, precision, reproducibility, and safety in surgical interventions. The Musculoskeletal Apparatus Network (RAMS Network) centers are equipped with advanced 3D laboratories for surgical simulation and planning, aligned with the overarching goal of improving surgery quality through "in-silico" medicine (ISM) principles. At present, numerous complex surgeries involving Virtual Surgical Planning (VSP) and sterilizable 3D-printed Patient-Specific Instruments (PSI) and/or Graft-Specific Instruments (GSI) are being simulated and performed at the Rizzoli Institute. Preliminary data from previous protocols indicate a significant reduction in surgical time with the implementation of VSP and the utilization of PSI and GSI. The aim of this study is to enhance the current process of simulating, planning, and designing surgical support tools within 3D Printing Point-of-Care (3D POC) facilities. To achieve this, it is imperative to expand case volumes and systematically organize, categorize, and standardize simulation and planning procedures.

Participants needed: 100
Trial details
Age: 2-40Biological sex: AllType: InterventionalSponsor: Istituto Ortopedico RizzoliUpdated: Dec 26, 2025Locations: 7
Eligibility criteria

Diagnosis of musculoskeletal disease (MSD) of the limbs; [+2]

Patients who refuse to participate in the study [+3]

Status: Not yet recruiting

Effects of Emicizumab Treatment in Patients With Hemophilia A

The aim of our study is to investigate the effects of emicizumab treatment on the musculoskeletal system in children with hemophilia A.

Participants needed: 20
Trial details
Age: 1-18Biological sex: MaleType: ObservationalSponsor: Hasan Kalyoncu UniversityUpdated: Sep 24, 2025Locations: 1Duration: 6 Months
Eligibility criteria

Children who are under 18 years of age, [+5]

Status: Not yet recruiting

Prospective Evaluation Assessing U2 MB™ Total Knee System

The goal of this study is to evaluate the safety and effectiveness of the United Orthopaedics Mobile Bearing Total Knee System (U2 MB™ Knee) in patients undergoing total knee replacement surgery due to end-stage knee osteoarthritis. The main questions it aims to answer are: 1\. What is the component survivorship of the U2 MB™ Knee system at 1, 3, 5, and 10 years? Participants will: 1. Return for follow-up assessments at Year 1, Year 3, Year 5, and Year 10 after surgery 2. Undergo clinical evaluations including functional outcome scoring, radiographic imaging. This study will take place across three investigational sites and will involve 150 knee replacements using U2 MB™ components. The study's objectives include assessing early to long-term outcomes in terms of implant survivorship, clinical function, patient satisfaction, radiological findings, and overall safety of the device over a 10-year period.

Participants needed: 150
Trial details
Age: 21+Biological sex: AllType: ObservationalSponsor: MSK Doctors & Associates LtdUpdated: May 30, 2025Duration: 13 Years
Eligibility criteria

All patients suitable for a cemented Total Knee Replacement, MBC design [+3]

Skeletally immature (less than 21 years of age) at time of implantation [+7]

Status: Recruiting

Evaluation of Non-Surgical and Arthroscopic Treatment for Hip Microinstability

Microinstability of the hip joint is an important cause of hip pain and reduced hip function in young and active individuals. Hip microinstability is due to extraphysiologic hip motion and could be secondary to acetabular dysplasia, connective tissue disorder, macrotrauma, microtrauma, iatrogenic- and idiopathic causes. Treatment for hip microinstability is initiated with non-surgical treatment consisting of physiotherapy aimed mainly at stability. If non-surgical treatment fails, surgery with arthroscopic plication of the hip joint capsule is the preferred method. This study evaluates non-surgical and arthroscopic treatment for hip microinstability regarding hip function and adverse events.

Participants needed: 26
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Göteborg UniversityUpdated: Mar 12, 2025Locations: 3
Eligibility criteria

Hip microinstability [+1]

Hip osteoarthritis [+3]

Status: Recruiting

RCT of Combination Effect of Vibration Treatment and HMB Supplementation on Myosteatosis and NMJ Degeneration

The investigators' pre-clinical study confirms the positive effects of combined treatment (VT + HMB) on reducing fat-to-lean tissue ratio, intramuscular fat infiltration and increasing muscle strength in sarcopenia animal model. The results showed that fat mass could be decreased by \~32%, while histology Oil Red O staining indicated a decrease of fat by almost 60%; in contrast, lean muscle mass increased by \~14%. On muscle strength, combined treatment increased twitch force, tetanic force and grip strength by \~30-66%. These in vivo results are very encouraging and the investigators should explore its potential in clinical translation. As VT and HMB supplement have been commercially available and their compliance rates are satisfactory, they can be translated to clinical application easily. The investigators' next step is to confirm its clinical efficacy, so that sarcopenia becomes a new indication of VT and HMB. The hypothesis is that combined treatment of VT and HMB can retard the progression of sarcopenia in human, in terms of muscle mass, muscle strength and performance.

Participants needed: 200
Trial details
Age: 60+Biological sex: AllType: InterventionalSponsor: Chinese University of Hong KongUpdated: Feb 13, 2025Locations: 3
Eligibility criteria

Subjects aged 60 years or above [+4]

Subjects with pathological bone diseases [+7]